Directory
Headshot of Terry Elton

Terry Elton

Professor

Pharmacy Education and Innovation
Research Areas: Division of Pharmacy Education and Innovation

555 Parks Hall

elton.8@osu.edu
(614) 292-1400

Professional Interests

MicroRNAs (miRNAs) are a family of small nonprotein-coding RNAs that have emerged as important regulators in cardiac developmental and pathological processes. They are genomically encoded and are initially transcribed as part of much longer molecules that become processed into a mature ~22-nucleotide-long form. miRNAs are generally regarded as negative regulators of gene expression that inhibit translation and/or promote messenger RNA (mRNA) degradation by base-pairing to complementary sequences within protein-coding mRNA transcripts. Hundreds of human miRNA genes have been identified and bioinformatic analyses indicate that miRNAs might regulate the expression of more than a third of human protein-coding genes, highlighting the potential magnitude of their influence on gene expression. Given the increasingly important roles of miRNAs in heart development and function, the lab hypothesizes that aberrant regulation of miRNAs may play a role in mediating cardiovascular disease. Therefore, one major focus of Elton’s laboratory investigates miRNA expression and gene regulation in various cardiovascular diseases.

Education

  • 1988, Postdoctoral, University of Alabama
  • 1987, Postdoctoral, Washington State University
  • 1986, PhD, Washington State University, Biochemistry
  • 1981, BS, Weber State University, Chemistry

Honors

  • Clinical Research Award, 1988 - 1988
  • Finalist, 1988 - 1988
  • Summer Graduate Research Assistantship, 1984 - 1984
  • A.C. Glen King Award, 1981 - 1981

Publications

  • Hernandez VA, Carvajal-Moreno J, Papa JL, Shkolnikov N, Li J, Ozer HG, Yalowich JC, Elton TS. CRISPR/Cas9 Genome Editing of the Human Topoisomerase IIα Intron 19 5' Splice Site Circumvents Etoposide Resistance in Human Leukemia K562 Cells. Mol Pharmacol. 2021 Mar;99(3):226-241. doi: 10.1124/molpharm.120.000173. Epub 2021 Jan 14. PMID: 33446509; PMCID: PMC7919865.
  • Kania EE, Carvajal-Moreno J, Hernandez VA, English A, Papa JL, Shkolnikov N, Ozer HG, Yilmaz AS, Yalowich JC, Elton TS. hsa-miR-9-3p and hsa-miR-9-5p as Post-Transcriptional Modulators of DNA Topoisomerase IIα in Human Leukemia K562 Cells with Acquired Resistance to Etoposide. Mol Pharmacol. 2020 Mar;97(3):159-170. doi: 10.1124/mol.119.118315. Epub 2019 Dec 13. PMID: 31836624; PMCID: PMC6978698.
  • Elton TS, Ozer HG, Yalowich JC. Effects of DNA topoisomerase IIα splice variants on acquired drug resistance. Cancer Drug Resist. 2020;3(2):161-170. doi: 10.20517/cdr.2019.117. Epub 2020 Feb 27. PMID: 32566920; PMCID: PMC7304410.
  • Kanagasabai R, Karmahapatra S, Kientz CA, Yu Y, Hernandez VA, Kania EE, Yalowich JC, Elton TS. The Novel C-terminal Truncated 90-kDa Isoform of Topoisomerase IIα (TOP2α/90) Is a Determinant of Etoposide Resistance in K562 Leukemia Cells via Heterodimerization with the TOP2α/170 Isoform. Mol Pharmacol. 2018 May;93(5):515-525. doi: 10.1124/mol.117.111567. Epub 2018 Mar 7. PMID: 29514855.
  • Kanagasabai R, Serdar L, Karmahapatra S, Kientz CA, Ellis J, Ritke MK, Elton TS, Yalowich JC. Alternative RNA Processing of Topoisomerase IIα in Etoposide- Resistant Human Leukemia K562 Cells: Intron Retention Results in a Novel C-Terminal Truncated 90-kDa Isoform. J Pharmacol Exp Ther. 2017 Jan;360(1):152-163. doi: 10.1124/jpet.116.237107. Epub 2016 Nov 10. PMID: 27974648.
  • Martin MM, Buckenberger JA, Knoell DL, Strauch AR, Elton TS. Retraction notice to "TGF-β1 regulation of human AT1 receptor mRNA splice variants harboring exon 2". Mol Cell Endocrinol. 2016 Oct 15;434:288. doi: 10.1016/j.mce.2016.08.003. PMID: 27519873.
  • Elton TS, Yalowich JC. Experimental procedures to identify and validate specific mRNA targets of miRNAs. EXCLI J. 2015 Jul 2;14:758-90. doi: 10.17179/excli2015-319. PMID: 27047316; PMCID: PMC4817421.
  • Elton TS, Selemon H, Elton SM, Parinandi NL. Regulation of the MIR155 host gene in physiological and pathological processes. Gene. 2013 Dec 10;532(1):1-12. doi: 10.1016/j.gene.2012.12.009. Epub 2012 Dec 14. PMID: 23246696.
  • Wu Y, Crawford M, Mao Y, Lee RJ, Davis IC, Elton TS, Lee LJ, Nana-Sinkam SP. Therapeutic Delivery of MicroRNA-29b by Cationic Lipoplexes for Lung Cancer. Mol Ther Nucleic Acids. 2013 Apr 16;2(4):e84. doi: 10.1038/mtna.2013.14. PMID: 23591808; PMCID: PMC3650246.
  • Pleister A, Selemon H, Elton SM, Elton TS. Circulating miRNAs: novel biomarkers of acute coronary syndrome? Biomark Med. 2013 Apr;7(2):287-305. doi: 10.2217/bmm.13.8. PMID: 23547823.
  • Martin MM, Lee EJ, Buckenberger JA, Schmittgen TD, Elton TS. MicroRNA-155 regulates human angiotensin II type 1 receptor expression in fibroblasts. J Biol Chem. 2013 Feb 8;288(6):4226. doi: 10.1074/jbc.A112.601496. PMID: 23690058; PMCID: PMC3567671.
  • Martin MM, Buckenberger JA, Jiang J, Malana GE, Nuovo GJ, Chotani M, Feldman DS, Schmittgen TD, Elton TS. The human angiotensin II type 1 receptor +1166 A/C polymorphism attenuates microRNA-155 binding. J Biol Chem. 2013 Feb 8;288(6):4227. doi: 10.1074/jbc.A112.701050. PMID: 23690059; PMCID: PMC3567672.
  • Kuhn DE, Nuovo GJ, Terry AV Jr, Martin MM, Malana GE, Sansom SE, Pleister AP, Beck WD, Head E, Feldman DS, Elton TS. Chromosome 21-derived microRNAs provide an etiological basis for aberrant protein expression in human down syndrome brains. J Biol Chem. 2013 Feb 8;288(6):4228. doi: 10.1074/jbc.A109.033407. PMID: 23690060; PMCID: PMC3567673.